D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.

Duffaud F, van der Burg ME, Namer M, Vergote I, Willemse PHB, ten Bokkel Huinink W, Guastalla JP, Nooij, Kerbrat P, Piccart M, Tumolo S, Favalli G and 8 more

Show all authors

van der Vange N, Lacave AJ, Wils J, Splinter TA, Einhorn N, Roozendaal KJ, Rosso R, Vermorken JB

Anti-cancer drugs1 Feb 2001Cited by 19 (Europe PMC)

PMID11261890DOI10.1097/00001813-200102000-00010PepBankPUB-11261890

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with previously treated progressive ovarian cancer, triptorelin produced no objective responses.
In plain wordsIn patients with previously treated ovarian cancer, no objective responses occurred with triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableObjective response
Study
n = 74
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg on days 1, 8 and 28, then every 4 weeks · intramuscular · Until tumor progressionAs given in this study (human).
Source sentences
Summary
No objective responses were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees).
Summary · context
Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression.
Report a problemFND-1126189001
02HumanNon-randomized trialEfficacy outcome
In all ovarian cancer patients treated with triptorelin, median survival was 4 months.
In plain wordsIn all ovarian cancer patients treated with triptorelin, median survival was 4 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSurvival in all patients
Study
n = 74
Outcome group
Mortality · Cancer
Studied dose
3.75 mg on days 1, 8 and 28, then every 4 weeks · intramuscular · Until tumor progressionAs given in this study (human).
Measurements
Median survival
4 months
all patients
Source sentences
Summary
The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees).
Summary · context
Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression.
Report a problemFND-1126189006
03HumanNon-randomized trialEfficacy outcome
In evaluable ovarian cancer patients, 11 of 68 had stable disease during triptorelin treatment.
In plain wordsIn evaluable ovarian cancer patients, 11 of 68 had stable disease during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStable disease
Study
n = 68
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg on days 1, 8 and 28, then every 4 weeks · intramuscular · Until tumor progressionAs given in this study (human).
Measurements
Stable disease
11 patients
evaluable patients
Stable disease
16%
evaluable patients
Source sentences
Summary
Eleven out of 68 evaluable patients (16%) had stable disease.
2 context sentences(design, population, supporting numbers)
Summary · context
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees).
Summary · context
Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression.
Report a problemFND-1126189002
04HumanNon-randomized trialEfficacy outcome
In all evaluable ovarian cancer patients treated with triptorelin, median progression-free survival was 2 months.
In plain wordsIn all evaluable ovarian cancer patients treated with triptorelin, median time without progression was 2 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableProgression-free survival in evaluable patients
Study
n = 68
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg on days 1, 8 and 28, then every 4 weeks · intramuscular · Until tumor progressionAs given in this study (human).
Measurements
Median progression-free survival
2 months
all evaluable patients
Source sentences
Summary
The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees).
Summary · context
Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression.
Report a problemFND-1126189004
05HumanNon-randomized trialEfficacy outcome
In ovarian cancer patients with stable disease during triptorelin treatment, median progression-free survival was 5 months.
In plain wordsIn ovarian cancer patients with stable disease during triptorelin treatment, median time without progression was 5 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableProgression-free survival in stable disease
Study
n = 11
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg on days 1, 8 and 28, then every 4 weeks · intramuscular · Until tumor progressionAs given in this study (human).
Measurements
Median progression-free survival
5 months
patients with disease stabilization
Source sentences
Summary
The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees).
Summary · context
Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression.
Report a problemFND-1126189003
06HumanNon-randomized trialEfficacy outcome
In ovarian cancer patients with stable disease during triptorelin treatment, median survival was 17 months.
In plain wordsIn ovarian cancer patients with stable disease during triptorelin treatment, median survival was 17 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSurvival in stable disease
Study
n = 11
Outcome group
Mortality · Cancer
Studied dose
3.75 mg on days 1, 8 and 28, then every 4 weeks · intramuscular · Until tumor progressionAs given in this study (human).
Measurements
Median survival
17 months
patients with disease stabilization
Source sentences
Summary
The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees).
Summary · context
Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression.
Report a problemFND-1126189005
07HumanNon-randomized trialSafety outcome
In previously treated ovarian cancer patients, incidental hot flushes were the only reported adverse events during triptorelin treatment.
In plain wordsIn previously treated ovarian cancer patients, incidental hot flushes were the only reported adverse events during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableHot flushes
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg on days 1, 8 and 28, then every 4 weeks · intramuscular · Until tumor progressionAs given in this study (human).
Source sentences
Summary
The treatment was well tolerated; the only reported adverse events were incidental hot flushes.
2 context sentences(design, population, supporting numbers)
Summary · context
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees).
Summary · context
Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression.
Report a problemFND-1126189008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.